Information Provided By:
Fly News Breaks for July 19, 2018
RIGL
Jul 19, 2018 | 07:54 EDT
Jefferies analyst Eun Yang says her poll of 30 U.S. hematologists points to more rapid uptake for Rigel Pharmaceuticals' Tavalisse uptake and likely upside to current estimates. The survey is "particularly interesting" in light of the recent market selloff on launch, as it suggests the launch, especially in medium term, should go "very well," Yang tells investors in a research note. The poll results indicate potentially earlier/consistent use of Tavalisse as hematologists become more familiar with the drug, she adds. Yang has a Buy rating on Rigel with a $7 price target.
News For RIGL From the Last 2 Days
There are no results for your query RIGL